|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In addition, the correlation between the percentage of ICOS<sup>+</sup> T cells in tumor tissue and survival was detected.
|
30361907 |
2020 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
<b>Results:</b> Both ICOS<sup>+</sup>Foxp3<sup>+</sup>Treg cells (P=0.0341 and P=0.0298, respectively) and pDC (<i>P</i>=0.0237 and <i>P</i>=0.0083, respectively) in peripheral blood and tumor tissue could predict poor clinical outcome in GC patients.
|
31777600 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Altogether, our results indicate that a combination of anti-ICOS mAb and chemotherapy controls tumor growth in humanized mice, opening new perspectives for the treatment of breast cancer.
|
31143518 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Thus, this work provides strong support for the development of combinatorial therapies involving anti-CTLA-4 blockade and ICOS agonist tumor-targeting agents.
|
31405808 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
An agonist CD40 antibody based immunotherapy was less efficient at promoting tumor regression in elderly mice, which may be due to: (i) failure of elderly CD8<sup>+</sup> T cells to up-regulate perforin, and (ii) increased expression of multiple regulatory markers on CD11c<sup>+</sup> cells and T cells in elderly tumor-draining lymph nodes (including CD73, PD-1, ICOS, LAG-3, and TGF-β).
|
30560130 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
<b>Objective:</b> To improve dendritic cells (DCs) function, we targeted DCs to over express CD40 and inducible costimulator ligand (ICOSL) costimulatory molecules along with total messenger RNA (mRNA) of tumor cells to achieve a safe and effective system for treatment of tumor.
|
30265161 |
2018 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
In comparison, Treg cells infiltrating melanomas displayed lower FOXP3, PD-1, 4-1BB, and ICOS expression and were less potent suppressors of CD8 T-cell proliferation.<b>Conclusions:</b> The highly activated phenotype of ovarian tumor-infiltrating Treg cells may be a key component of an immunosuppressive tumor microenvironment.
|
30065096 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
ICOS costimulation generates Th17 cells with durable memory responses to tumor.
|
28422756 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
There were more immune-suppressing Tregs infiltrated into tumor after treatment with tumor cell vaccine, and ICOS blocking could deplete the infiltrated Tregs, and T lymphocytes increased more dramatically in the combination therapy group.
|
28923424 |
2017 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
CTLA-4 blockade led to the reduction of a suppressive CD4(+) T cell subset expressing Lag3, ICOS, IL-10 and Egr2 with a concomitant rise in IL-2-producing effector cells that lost FoxP3 expression and accumulated in regressing tumors.
|
25582080 |
2015 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Moreover, ICOS-Fc downmodulated the phosphorylation of focal adhesion kinase and the expression of β-Pix in both HUVECs and tumor cell lines.
|
24729612 |
2014 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Finally, we analysed the expression of MiR101, a putative partner of ROQUIN involved in the modulation of ICOS expression and found similar levels of expression in tumor and reactive TFH.
|
23825522 |
2013 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Moreover, ICOS promoted the robust expansion of IL-17(+)IFN-γ(+) human T cells, and the antitumor activity of these cells after adoptive transfer into mice bearing large human tumors was superior to that of cells expanded with CD28.
|
20980695 |
2010 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
B(7-1),B(7)H(1),B(7)H(2),ICOS mRNA were detected in both cancer cells and tumor infiltrating lymphocytes (TIL).
|
16237760 |
2005 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
To this end, after introducing the ICOS and its ligand and comparing the murine and human 'knockout', the role of the ICOS in parasitic and viral infections, asthma, autoimmunity, transplantation immunology, and tumor surveillance will be discussed.
|
14612664 |
2003 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
HPO |
|
|
|